Literature DB >> 10998536

Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system.

E Schlicker1, M Morari.   

Abstract

In this article, the effect of nociceptin (orphanin FQ) on transmitter release in the central nervous system in vitro and in vivo is reviewed. Nociceptin inhibits the electrically or K(+)-evoked noradrenaline, dopamine, serotonin, and glutamate release in brain slices from guinea-pig, rat, and mouse. This effect is usually naloxone-resistant but antagonized by OP(4) receptor antagonists like [Phe(1)psi(CH(2)-NH)Gly(2)]-nociceptin(1-13)NH(2). In the rat in vivo, nociceptin diminishes acetylcholine release in the striatum, reduces dopamine release, and prevents the stimulatory effect of morphine on this transmitter in the nucleus accumbens and also elevates extracellular glutamate and gamma-aminobutyric acid levels in mesencephalic dopaminergic areas. The effect of nociceptin on the mesencephalic dopaminergic system might explain its actions on motor behavior.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998536     DOI: 10.1016/s0196-9781(00)00233-3

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  34 in total

1.  Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors.

Authors:  K Flau; A Redmer; S Liedtke; M Kathmann; E Schlicker
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex.

Authors:  Benjamin Berger; Anna Katharina Rothmaier; Franziska Wedekind; Josef Zentner; Thomas J Feuerstein; Rolf Jackisch
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

3.  Activation of nociceptin/orphanin FQ peptide receptors disrupts visual but not auditory sensorimotor gating in BALB/cByJ mice: comparison to dopamine receptor agonists.

Authors:  Aurelia Ces; David Reiss; Ondine Walter; Jürgen Wichmann; Eric P Prinssen; Brigitte L Kieffer; Abdel-Mouttalib Ouagazzal
Journal:  Neuropsychopharmacology       Date:  2011-08-31       Impact factor: 7.853

Review 4.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

5.  Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro.

Authors:  Anna Siniscalchi; Donata Rodi; Michele Morari; Matteo Marti; Sabrina Cavallini; Silvia Marino; Lorenzo Beani; Clementina Bianchi
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

6.  Nociceptin Receptors Upregulated in Cocaine Use Disorder: A Positron Emission Tomography Imaging Study Using [11C]NOP-1A.

Authors:  Rajesh Narendran; Savannah Tollefson; Michael L Himes; Jennifer Paris; Brian Lopresti; Roberto Ciccocioppo; N Scott Mason
Journal:  Am J Psychiatry       Date:  2019-05-06       Impact factor: 18.112

7.  Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior.

Authors:  Celia Goeldner; David Reiss; Brigitte L Kieffer; Abdel-Mouttalib Ouagazzal
Journal:  Hippocampus       Date:  2010-08       Impact factor: 3.899

8.  NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.

Authors:  Victor A D Holanda; Wilton B Santos; Laila Asth; Remo Guerrini; Girolamo Calo'; Chiara Ruzza; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2018-08-25       Impact factor: 4.530

Review 9.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

10.  Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors.

Authors:  Alexander Kuzmin; Johan Sandin; Lars Terenius; Sven Ove Ogren
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.